Method for treating anxiety
AssigneeEli Lilly and Company
InventorsNeil C. Bodick, Franklin P. Bymaster, Walter W. Offen, Harlan E. Shannon
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for treating anxiety in humans using compounds which modulate a muscarinic receptor.
Claims4
A method for treating anxiety comprising administering to a human in need thereof an antianxiety dose of a compound of the formula:
- ##STR38## wherein one of X and Y is hydrogen and the other is Z;
- Z is a 5-membered aromatic ring comprising a 3-membered divalent residue and two or three nitrogen atoms, wherein any amino nitrogen can be substituted by a C.sub.1-2 alkyl, cyclopropyl or propargyl group;
- r is 2 or 3;
- and
- s is 1 or 2;
- provided that, when Y is hydrogen, s is 1;
- or a pharmaceutically acceptable salt or solvate of the compound.
A method for treating anxiety comprising administering to a human in need thereof an antianxiety dose of the compound 4-(2H-1,2,3-triazol-4-yl)-1-azabicyclo2.2.1!heptane, or a pharmaceutically acceptable salt or solvate of the compound.
A method for treating anxiety comprising administering to a human in need thereof an antianxiety dose of the compound 3-(2-methyltetrazol-5-yl)-1-azabicyclo2.2.1!heptane, or a pharmaceutically acceptable salt or solvate of the compound.
A method for treating anxiety comprising administering to a human in need thereof an antianxiety dose of the compound (3R,4R)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo2.2.1!heptane, or a pharmaceutically acceptable salt or solvate of the compound.
Dependencies are inferred from the claim text.